ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Ominous Note: Magnuson Hints Senate May Cut NCI Budget 5% Under President’s 1980 Request

March 9, 1979

EORTC Places Same Number on Phase 2-3 Trials As In U.S.

December 12, 1986

Six More CCOPS In Funding Range For Recompetition

February 9, 1990

Groups Urge Congress To Enact NIH Budget Increase; Encourage Individual Letters

November 3, 1995

After Furlough, Blizzard, NCI Struggles to Clear Backlog and Resume Business

January 19, 1996

Grantees Seek $433.5 Million for construction

November 17, 1978